therapeutic antibodies

Question 1

alemtuzumab

Answer 1

CD52
CLL (think alym = lymphocytes)

Question 2

bevacizumab

Answer 2

VEGF

colorectal cancer, renal cell carcinoma

Question 3

cetuximab

Answer 3

EGFR

stage IV colorectal cancer, head and neck cancer

Question 4

rituximab

Answer 4

CD20

B cell NHL, CLL, rheumatoid arthritis, ITP

Question 5

trastuzumab

Answer 5

HER2/neu

breast cancer

Question 6

adalimumab, infliximab

Answer 6

soluble TNF-alpha
IBD, rheumatoid arthritis, ankylosing spondylitis, psoriasis

**etanercept is a decoy TNF-alpha receptor and not a monoclonal antibody

Question 7

eculizumab

Answer 7

complement protein C5

paroxysmal nocturnal hemoglobinuria

Question 8

natalizumab

Answer 8

alpha4-integrin
MS, Crohn

*alpha4-integrin: WBC adhesion
risk of PML in patients with JC virus

Question 9

abciximab

Answer 9

platelet IIb/IIIa glycoproteins
antiplatelet agent for prevention of ischemic complications in pts undergoing cardiac stents

*II times III is absiximab

Question 10

denosumab

Answer 10

RANKL

osteoporosis- inhibits osteoclast maturation (mimics osteoprotegerin)

Question 11

digoxin immune Fab

Answer 11

digoxin

antidote for digoxin toxicity

Question 12

omalizumab

Answer 12

IgE

allergic asthma; prevents IgE binding to FcERI

Question 13

palivizumab

Answer 13

RSV F protein
RSV ppx for high risk infants

**paliVI = VIrus

Question 14

ranibizumab, bevacizumab

Answer 14

VEGF

neovascular age related macular degeneration